ESTABLISHMENT LABS HOLDINGS INC.
No SEC Form 4 filings for $ESTA in the last 30 days.
See all $ESTA insider activity →TD Cowen reaffirmed a 'Buy' rating and $117 price target for Establishment Labs (ESTA). The stock is trading at a 9.0% discount to its GF Value™ of $65.35. ESTA has a GF Score™ of 78/100, indicating strong growth and valuation metrics, but weaker financial strength and profitability. 4 gurus hold positions, with 3 adding recently.
Establishment Labs extended its silicone supply agreement with NuSil Technology to 2031, with options for five one-year renewals. The amendment updates terms for manufacturing, pricing, and intellectual property, ensuring supply reliability. According to the company, this supports operational planning.
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 14, 2026, Establishment Labs Holdings Inc. (the “Company”), through its wholly owned subsidiary, Establishment Labs, S.A. (“ELSA”), entered into Amendment No. 3 (“Amendment No. 3”) to the Master Supply Agreement (th
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning ESTA (ESTABLISHMENT LABS HOLDINGS INC.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 1 bearish.
Recent ESTA coverage spans financial news, market movers and regulation.
The reaffirmed Buy rating may generate modest buying pressure as investors consider the $117 target versus current price.
The extension secures long‑term material supply, reducing operational risk for ESTA.
The amendment secures a longer supply relationship and may improve cost stability for ESTA, but no immediate financial impact is disclosed.
Analyst upgrade and higher target suggest potential upside.
The stock is under pressure from recent insider selling and a sharp price drop.
AlphAI scores every news story that mentions ESTA with an AI model for sentiment and relevance, and aggregates insider trades from ESTABLISHMENT LABS HOLDINGS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TD Cowen reaffirmed a 'Buy' rating and $117 price target for Establishment Labs (ESTA). The stock is trading at a 9.0% discount to its GF Value™ of $65.35. ESTA has a GF Score™ of 78/100, indicating strong growth and valuation metrics, but weaker financial strength and profitability. 4 gurus hold positions, with 3 adding recently.
1 min readEstablishment Labs extended its silicone supply agreement with NuSil Technology to 2031, with options for five one-year renewals. The amendment updates terms for manufacturing, pricing, and intellectual property, ensuring supply reliability. According to the company, this supports operational planning.
1 min readESTABLISHMENT LABS HOLDINGS INC. (ESTA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 14, 2026, Establishment Labs Holdings Inc. (the “Company”), through its wholly owned subsidiary, Establishment Labs, S.A. (“ELSA”), entered into Amendment No. 3 (“Amendment No. 3”) to the Master Supply Agreement (th
1 min readStifel initiated coverage on Establishment Labs (NASDAQ:ESTA) with a Buy rating and $85 price target, citing expected growth and market share gains. The stock has fallen 8.5% in the past week. The company reported Q2 2026 revenue of $67.5M, beating estimates, and raised its full-year revenue outlook. Analysts expect EBITDA positivity by Q3 2025 and positive free cash flow by H2 2026.
2 min readEstablishment Labs Holdings Inc (ESTA) shares fell 5.2% to $58.45 on October 13, 2026, continuing a 19.8% year-to-date decline. The stock is undervalued by 10.5% according to GF Value™, with a GF Score™ of 76/100. Insiders sold $36.9M in shares over the past year, while some gurus increased their positions. The company shows strong growth but weak financial strength and profitability.
2 min readEstablishment Labs Holdings (ESTA) received FDA clearance for 28 additional implant sizes. The stock has declined 25.80% over 90 days but gained 61.41% over one year. Analysts see a fair value of $92.00, while the stock closed at $65.29. The company faces risks related to market concentration and profitability.
2 min readEstablishment Labs received FDA approval to add 28 sizes to its Motiva breast implants in the U.S. The expanded range will be available before year-end, according to the company.
1 min readEstablishment Labs (ESTA) reported Q2 revenue of $67.5M, up 31.7% YoY, with gross margins at 70.6%. Adjusted EBITDA turned positive at $3.7M. The company raised full-year revenue guidance to $269M-$271M. Despite operational improvements, it posted a net loss of $11.7M and faces institutional skepticism due to debt and cash burn concerns.
3 min readTD Securities predicts Establishment Labs' stock could rise due to increased demand for breast augmentation procedures driven by GLP-1 drugs. The bank maintains a buy rating and $117 price target, implying 68% upside. GLP-1 use and cosmetic surgery procedures have risen, benefiting the company's Motiva and Preservé breast implant lines. All nine analysts covering the stock recommend buying.
2 min readEstablishment Labs (NASDAQ:ESTA) reported Q2 updates on its Motiva breast implant business. Outside the U.S. revenue rose 4.4% to $42.8M, with Europe up 16%. Its Minimally Invasive platform generated $12.1M revenue, nearing 15% of full-year global revenue. Gross margin improved to 70.6%. Cash was $71.2M. FDA site audits began for U.S. reconstruction; no material revenue expected until 2027.
6 min read
